Effectiveness of oral metronomic Vinorelbine versus Docetaxel as second-line treatment in Non-Small Cell Lung Cancer patients in real life

被引：0
|
作者：
Nikolakopoulou, Asimina [1 ]
Tzimopoulos, Konstantinos [1 ]
Tsaroucha, Emily [1 ]
Kavvada, Katerina [1 ]
Rapti, Angeliki [1 ]
机构：
[1] Hosp Chest Dis, Pulm Dept 2, Athens, Greece
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Lung cancer; Treatments; Lung cancer - management;
D O I：
10.1183/13993003.congress-2020.1697
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1697
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
    Calpe-Armero, Pablo
    Ferriols-Lisart, Rafael
    Ferriols-Lisart, Francisco
    Perez-Pitarch, Alejandro
    CHEMOTHERAPY, 2017, 62 (06) : 374 - 380
  • [2] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    LUNG CANCER, 2005, 49 : S248 - S248
  • [3] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [4] Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
    Shi, Yafei
    Chen, Wei
    Zhang, Yujun
    Bo, Mingming
    Li, Chunyu
    Zhang, Mingyu
    Li, Guohui
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
  • [5] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [6] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    PharmacoEconomics, 2004, 22 : 581 - 589
  • [7] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [8] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [9] A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
    Goern, Michael
    Habermann, Christian R.
    Anige, Manuela
    Thoem, Ina
    Schuch, Gunter
    Andritzky, Birte
    Brandl, Stefan
    Burkholder, Iris
    Edler, Lutz
    Hossfeld, Dieter Kurt
    Bokemeyer, Carsten
    Laack, Eckart
    ONKOLOGIE, 2008, 31 (04): : 185 - 189
  • [10] Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer
    Chelis, L.
    Xenidis, N.
    Amarantidis, K.
    Prassopoulos, P.
    Chamalidou, E.
    Neanidis, K.
    Mikroulis, D.
    Chatzaki, E.
    Karakitsos, P.
    Kakolyris, S.
    CHEMOTHERAPY, 2010, 56 (05) : 353 - 358
12345